GlassScriptPhysician profile
Ellen F Branham
NPI 1801551114
$1,390.81
in general payments reported to CMS, 2019-2025
28 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $606 · 2023: $262 · 2024: $305 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $165.30 | 2021-2023 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $150.23 | 2022-2024 | Opdivo |
| Menarini Silicon Biosystems, INC. | $113.46 | 2024 | |
| Adaptive Biotechnologies Corporation | $108.32 | 2023-2025 | Clonoseq |
| Amgen INC. | $74.17 | 2022 | |
| Theratechnologies INC. | $72.24 | 2022 | |
| Daiichi Sankyo INC. | $61.62 | 2022 | |
| Tactile Systems Technology INC | $57.06 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Siemens Medical Solutions USA, INC. | $51.15 | 2024 | Aria Radiation Therapy Management Software |
| Foundation Medicine, INC. | $50.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $43.23 | 2022 | |
| Mirati Therapeutics, INC. | $42.40 | 2023 | Krazati |
| Seagen INC. | $38.70 | 2021-2023 | Tukysa |
| Celgene Corporation | $35.31 | 2023 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $33.83 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $29.59 | 2023 | |
| Eisai INC. | $29.58 | 2022 | |
| Puma Biotechnology, INC. | $25.74 | 2022 | |
| Incyte Corporation | $24.71 | 2023 | Jakafi |
| Sobi, INC | $23.70 | 2022 | |
| Beigene USA, INC. | $23.70 | 2022 | |
| Octapharma USA, INC. | $22.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.42 | 2022 | |
| Kyowa Kirin, INC. | $21.33 | 2022 | |
| Merck Sharp & Dohme LLC | $20.19 | 2025 | Keytruda |
| Emd Serono, INC. | $18.00 | 2022 | |
| Genzyme Corporation | $17.35 | 2025 | |
| Glaxosmithkline, LLC. | $15.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Branham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.